Moreover, PD-L1 expression can be considered as a biomarker of poor prognosis in cancer patients, and some studies have shown a role of PD-L1 in the induction of anti-tumour immune responses, contributing to better prognosis after surgery [75–77]. This evidence concerns the gene CD274 and cancer.